Drugs for Neglected Diseases initiative (DNDi)
Dr Nathalie Strub-Wourgaft is part of the DNDi team since 2009, and holds over 35 years of experience in R&D and public health since the past 11 years. Dr Strub-Wourgaft is currently the Director of Neglected Tropical Diseases (NTDs) and acting ANTICOV Lead at DNDi. Dr Strub-Wourgaft provides strategic and technical oversight to a wide portfolio of R&D and access plans for therapeutic areas covering sleeping sickness, Chagas disease, cutaneous and visceral leishmaniasis, filarial diseases, mycetoma, and COVID-19, answering unmet medical needs for neglected populations. Prior to her current appointment, Dr Strub-Wourgaft held the Medical Director post at DNDi, where she oversaw clinical development of the DNDi kinetoplastid and mycetoma portfolio, and was also responsible for developing and supervising the organization’s quality, pharmacovigilance, and regulatory activities. Before her time at DNDi, Dr Strub-Wourgaft served as Clinical Development Director at Trophos, and held many related roles with Pfizer, Lundbeck, Asperva, and CROs. Dr Strub-Wourgaft graduated as Medical Doctor from Necker Hospital, Université René Descartes in Paris in 1983.
A Clinical Research Coalition Against COVID-19